Neopharm Inactive 10-Q2007 Q0 Quarterly report

Filed: 9 Nov 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: absorb, agent, aggressive, anaplastic, approach, ascertain, astrocytoma, attached, blinded, brainstem, Camptosar, catheter, caution, cavity, Central, cerebellum, cerebral, chemotherapeutic, chemotherapy, cognitive, commonly, compliant, composed, confirmed, convert, convertible, coordination, cord, cumulative, curtain, cytotoxic, destruction, diagnosed, enabling, entry, EVP, fatal, fill, filling, framework, goal, headcount, healthy, hope, ingredient, interval, intracranial, irinotecan, iron, Jeffrey, July, language, Larry, latch, leasehold, lessen, lung, main, memory, men, metabolite, microscopic, molecule, nearest, neurological, newly, ordinary, organization, organizational, ovarian, partially, PE, people, personality, placement, population, pressure, quality, Quantifying, radiation, randomized, reassessed, recombinant, refocusing, Registry, reorganization, resection, rollover, rounded, sensory, Sherman, shifted, single, small, space, spinal, spread, surgery, surgical, therapy, thousand, unharmed, visual, Wafer, women, wrote

Removed: accelerated, analyzed, announced, Aquilur, base, CEO, Chairman, depreciated, desired, director, disposition, Eastern, group, Hussey, intention, LErafAON, move, objectively, putative, Rahman, recommended, relation, resignation, royalty, serve, shortened, suit, timeline, traditionally, whichever, wholesale

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Neopharm similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States Code), the undersigned officer of NEOPHARM, Inc., a Delaware corporation (the “Company”), does hereby certify with respect to the Quarterly Report of the Company on Form 10-Q for the quarter ended September 30, 2006 as filed with the Securities and Exchange Commission (the “10-Q Report”) that:

(1) the 10-Q Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the 10-Q Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 9, 2006	/s/ Guillermo A. Herrera
	Guillermo A. Herrera
	Chief Executive Officer